Therapeutic compositions for treatment of ocular inflammatory disorders
The invention comprises a composition with means to inhibit the function of the inflammatory cytokine IL-17 and methods for using this composition to treat IL-17-mediated ocular inflammatory disorders. The invention also discloses devices for delivering this composition to the eye.
1. A method for reducing the severity of dry eye syndrome comprising
identifying a subject characterized as suffering from dry eye syndrome;
topically administering directly to an eye of a subject a composition that inhibits binding of an inflammatory interleukin-17 (IL-17) cytokine to an IL-17 receptor; and
inhibiting or reducing eye dryness associated with said dry eye syndrome, thereby reducing the severity of said dry eye syndrome, wherein said dry eye syndrome is a non-Sjogren's syndrome associated dry eye syndrome associated with meibomian gland dysfunction, and is not uveitis, intraocular conditions, or inflammation of interior tissues of the eye.
2. The method of claim 1 , wherein said identifying step comprises detection of a sign or symptom selected from the group consisting of eye dryness, scratching, stinging, itching, burning, irritation, pain, redness, inflammation, discharge, and excessive watering, and wherein said method inhibits or reduces the severity of at least one of said signs or symptoms.
3. The method of claim 1 , wherein said method comprises sequential or simultaneous administration of a composition that inhibits binding of an inflammatory IL-17 cytokine to an IL-17 receptor and a secondary composition.
4. The method of claim 1 , wherein the form of said composition is a solid, an ointment, a gel, a liquid, an aerosol, a mist, a polymer, a contact lens, a film, an emulsion, or a suspension.
5. The method of claim 1 , wherein said method does not comprise systemic administration or substantial dissemination to non-ocular tissue.
6. The method of claim 1 , wherein said composition further comprises a compound selected from the group consisting of a physiologically acceptable salt, poloxamer analogs with carbopol, carbopol/HPMC, carbopol-methyl cellulose, a mucolytic agent, carboxymethylcellulose (CMC), hyaluronic acid, cyclodextrin, and petroleum.
7. The method of claim 1 , wherein said method comprises administration of both a composition that inhibits binding of an inflammatory IL-17 cytokine to an IL-17 receptor and a second composition comprising one or more inflammatory antagonist(s).
8. The method of claim 1 , wherein said composition comprises:
(a) a monoclonal or polyclonal antibody;
(b) an antibody that targets an intracellular or extracellular IL-17 cytokine or IL-17 receptor;
(c) an antibody that binds to at least one intracellular or extracellular sequence of an IL-17 cytokine or IL-17 receptor;
(d) a single-chain antibody;
(e) a humanized, recombinant, or chimeric antibody;
(f) an antibody conjugated directly or indirectly to a compound that inhibits or modifies the activity of an IL-17 cytokine or an IL-17 receptor or
(g) a composition that inhibits or modifies the transcription, transcript stability, translation, modification, localization, secretion, or function of a polynucleotide or polypeptide encoding an inflammatory interleukin-17 cytokine or an IL-17 receptor.
9. The method of claim 1 , wherein said composition inhibits an activity of an inflammatory cytokine selected from the group consisting of IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F.
10. The method of claim 1 , wherein said composition inhibits an activity of an inflammatory cytokine receptor selected from the group consisting of IL-17RA, IL-17RB, IL-17RC, IL-17RD, IL-17RE, and IL-17RF.